Anti-MRSA effects of synergism of recombinant lysostaphin with biosynthesized silver nanoparticles.

BACKGROUND

Methicillin-resistant Staphylococcus aureus (MRSA) strains become a major challenge to public health and health provider due to their wide spread and resistance to wide spectrum of antibacterial agents.

AIM: This study aimed to characterize recombinant lysostaphin produced by Escherichia coli BL21(DE3) and to investigate the biosynthesis of silver nanoparticles (SNPs) by Candida albicans against MRSA.

METHODS

Samples were collected from vaginal samples. The methods included efficient cloning, expression, and purification of recombinant lysostaphin, a potent antibacterial enzyme targeting S. aureus, and achieved with advanced molecular techniques in E. coli BL21(DE3). The SNPs were synthesized using a biogenic approach with C. albicans, demonstrating stable and efficient silver ion reduction, as confirmed by ultraviolet-visible spectroscopy, scanning electron microscope, and Fourier-transform infrared spectroscopy (FTIR) analyses.

RESULTS

The antibacterial assays against MRSA strains of S. aureus showed significant inhibition by both lysostaphin and SNPs. The combination of biosynthesized SNPs/polyethylene glycol with lysostaphin exerted significant activity against tested bacteria, resulting in zone of growth inhibition of 20.33 ± 0.88 mm.

CONCLUSION

These findings suggest a promising synergistic antibacterial strategy, offering hope in the fight against MRSA. The study findings reveal that lysostaphin and SNPs could be effective in the treatment of MRSA-related infections, especially when used in combination.